Why 10,000 Aussies a year being forced to fund their own cancer treatment

21 July 2024 - Australia’s medicine subsidy scheme is so crippled that a staggering 10,000 patients a year are being forced ...

Read more →

More than 40,000 people could benefit after NICE recommends new ‘take at home’ pill for advanced prostate cancer

19 July 2024 - A new pill to treat advanced hormone sensitive prostate cancer that could benefit just over 40,000 ...

Read more →

Public Summary Documents (first time decisions not to recommend and deferrals) - March 2024 PBAC meeting

19 July 2024 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the March 2024 ...

Read more →

DUSC utilisation analysis public release documents (June 2024)

19 July 2024 - The utilisation analysis public release documents from the June 2024 DUSC meeting are now available. ...

Read more →

Outcome statement - June 2024 DUSC meeting

19 July 2024 - The outcome statement from the June 2024 DUSC meeting is now available. ...

Read more →

PHARMAC proposes to widen access to urinary tract infections treatment and fund a new epilepsy treatment

18 July 2024 - PHARMAC is consulting on improving access to treatment for urinary tract infections, as well as providing ...

Read more →

BC doctor calls on the province to cover obesity medications

17 July 2024 - A petition from Dr. Ali Zentner asking for more PharmaCare coverage has received almost 1,000 signatures. ...

Read more →

Rucaparib camsylate for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

8 July 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...

Read more →

Teclistamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments (review of previous guidance)

16 July 2024 - The Department of Health and Social Care has asked the NICE to review the guidance on ...

Read more →

CSL Behring announces positive reimbursement decision in Canada for Hemgenix (etranacogene dezaparvovec), the first gene therapy for haemophilia B

16 July 2024 - The positive decision from CADTH recognises the importance of this one-time, single dose innovative treatment for ...

Read more →

Elranatamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments

12 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

SMC - July 2024 decisions

 8 July 2024 - Voretigene neparvovec (Luxturna) was accepted for the treatment of adults and children with an extremely rare inherited ...

Read more →

Clinical benefit, reimbursement outcomes, and prices of FDA approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis

11 July 2024 - Project Orbis is a global initiative that aims to streamline regulatory review processes across international regulators in ...

Read more →

PHARMAC proposal to increase access to five medicines for cancer and other health conditions

12 July 2024 - PHARMAC is looking to increase access to five medicines for a number of cancers, including kidney ...

Read more →

Australian children with neuroblastoma given free access to 500,000 dollar cancer drug DFMO

10 July 2024 - Australian children and young adults with neuroblastoma, a cancer that affects the nervous system, will be ...

Read more →